In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.
The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
The group is proposing women ages 30 to 65 be screened with cervical cytology every three years or receive testing for high-risk HPV every five years.
Two researchers, who have both received grants from Epigenomics, noted in a JAMA letter that the USPSTF did not use data on the FDA-approved version of the test.
At HudsonAlpha's Genomic Medicine Conference University of North Carolina's Anya Prince discussed insurance coverage of genetic tests and preventive care.
The company said it completed about 54,000 Cologuard tests in Q2, and that the cumulative number of physicians ordering the test since its launch has risen to 41,000.
The GenomeWeb Index fell half a percent in June, underperforming the Dow Jones Industrial Average, but far outpacing the Nasdaq and Nasdaq Biotech Index.
However, the task force stopped short of recommending the use of Cologuard or other molecular assays over a variety of well-established non-molecular testing methods.
Researchers are hoping the 100,000-patient WISDOM study will lead to genetically informed breast cancer screening based on a woman's unique risk factors.
In draft recommendations, the guidelines body included the stool-based DNA test as an alternative screen strategy for colorectal cancer, a move the company did not expect.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.